Invivo Pharmacokinetic studies to investigate the enhancement of bioavailability of Lovastatin

Abstract

The main aim of this study is to intensify the bioavailability of drug which is having lower bioavailability (<5 %) like Lovastatin in the form of Solid lipid nanoparticle (SLN) carrier and Nanostructured lipid carrier (NLC) and also to choose the best carrier molecule among this two by performing the invivo pharmacokinetic studies. The NLC (N3) and SLN (S6) was formulated by homogenization technique by using various formulation variable like lipid concentration (Witepsol) and surfactant concentration (span 80) and process variables like homogenization time (5000 Revolutions Per Minute) and albino wistar rats were used for the evaluation of invivo pharmacokinetic studies. From the obtained outcome, it was winded up that the formulation of Nanostructured Lipid Carried and SLN was carried out by a optimized hot homogenization technique. The optimized preparation N3 and S6 evaluated for invivo pharmacokinetic studies and compare the enhancing efficiency of bioavailability between the SLN and NLC. From the invivo pharmacokinetic data, NLC confirms enhancement of bioavailability by 10.56% when compared to SLN and conventional dosage form that have bioavailability 7.5% and 5.6%. From the outcome data of the research and in-vivo pharmacokinetic data, it came to an conclusion that the Lovastatin encapsulated Nanostructured Lipid Carrier presented an increased bioavailability than SLN, by intensifying the Area Under Curve and Mean Residence Time in plasma drug concentration profile. Hence using Nanostructured lipid carrier in the formulation of drugs in Biopharmaceutical Classification System class II, like Lovastatin which have low bioavailability will assure a better drug delivery system.